Use of other medications with TUDORZA
Short-acting beta2 agonists
Steroids (oral and inhaled)
Clinical studies showed no increase in adverse drug reactions
Long-acting muscarinic antagonists
Short-acting muscarinic antagonists
Coadministration of TUDORZA with other anticholinergic drugs may lead to an increase in
No formal drug-interaction studies have been performed with TUDORZA1
TUDORZA is rapidly and extensively hydrolyzed to its alcohol and dithienylglycolic acid derivatives, which are
The absolute bioavailability of aclidinium bromide is approximately 6% in healthy volunteers
Not expected to alter the disposition of coadministered drugs metabolized by CYP450 enzymes, due to
low plasma levels achieved
To read Important Safety Information about TUDORZA, visit
Important Safety Information
TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder) is an anticholinergic indicated for the
long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema.
IMPORTANT SAFETY INFORMATION
TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).
Inhaled medicines, including TUDORZA, may cause paradoxical bronchospasm. In addition, immediate hypersensitivity reactions may occur after administration of TUDORZA. If either of these occurs, treatment with TUDORZA should be stopped and other treatments considered.
TUDORZA should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop.
Patients with a history of hypersensitivity reactions to atropine should be closely monitored for similar hypersensitivity reactions to TUDORZA. Use with caution in patients with severe hypersensitivity to milk proteins.
The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA vs placebo, respectively.
Please also see the full Prescribing Information.